Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 110-112

  Berentsen, Sigbjørn ^a  

^a HAUGESUND HOSPITAL   (Norway)

Author keywords

Fludarabine; Lymphoplasmacytic lymphoma; Rituximab; Waldenstr m

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; CLADRIBINE; COLD AGGLUTININ; CORTICOSTEROID; FLUDARABINE; HEMOGLOBIN; IMMUNOGLOBULIN M; RITUXIMAB; COLD AGGLUTININS; CRYOGLOBULIN;

ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW; CLINICAL TRIAL; COLD AGGLUTININ DISORDER; COLD AGGLUTININ SYNDROME; CYTOLYSIS; DISEASE ASSOCIATION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; NONHODGKIN LYMPHOMA; PHAGOCYTOSIS; PREVALENCE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA; BIOSYNTHESIS; BLOOD; IMMUNOLOGY; REVIEW;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; CRYOGLOBULINS; HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649522696     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.030     Document Type: Article

References (25)

1. Berentsen S, Beiske K, Tjonnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology 2007; 12:361-70.
2. Christenson WN, Dacie JV, Croucher BE, et al. Electrophoretic studies on sera containing high-titre cold haemagglutinins: identification of the antibody as the cause of an abnormal gamma 1 peak. Br J Haematol 1957; 3:262-75.
3. Harboe M, van Furth R, Schubothe H, et al. Exclusive occurrence of K chains in isolated cold haemagglutinins. Scand J Haematol 1965; 2:259-66.
4. Berentsen S, Bo K, Shammas FV, et al. Chronic cold agglutinin disease of the "idiopathic" type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS 1997; 105:354-62.
5. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006; 91:460-6.
6. Stone MJ, Merlini G, Pascual V. Autoantibody activity in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5:225-9.
7. Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Clin Res Ed) 1981; 282:2023-7.
8. Ulvestad E, Berentsen S, Bo K, et al. Clinical immunology of chronic cold agglutinin disease. Eur J Haematol 1999; 63:259-66.
9. Pascual V, Victor K, Spellerberg M, et al. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol 1992; 149:2337-44.
10. Jaffe CJ, Atkinson JP, Frank MM. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J Clin Invest 1976; 58:942-9.
11. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103:2925-8.
12. Owen RG, Treon SP, Al Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:110-5.
13. Wang M, Zhou Y, Wang H, et al. Trends and geographic variations in the incidence of Waldenström's macroglobulinemia in the United States over 17 years from 1988 to 2004. 5th International Workshop on Waldenstrom's Macroglobulinemia. Abstract 101. Stockholm 2008.Available at:
14. Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 1982; 72:915-22.
15. Stone MJ, McElroy YG, Pestronk A, et al. Human monoclonal macroglobulins with antibody activity. Semin Oncol 2003; 30:318-24.
16. Dimopoulos MA, Hamilos G, Zervas K, et al. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol 2003; 14:1299-305.
17. Cesana C, Barbarano L, Miqueleiz S, et al. Clinical characteristics and outcome of immunoglobulin M related disorders. Clin Lymphoma 2005; 5:261-4.
18. Berentsen S, Tjonnfjord GE, Shammas FV, et al. No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol 2000; 65:88-90.
19. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004; 101:2593-8.
20. Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 2006; 47:253-60.
21. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20:444-9.
22. Berentsen S and Tjonnfjord GE. Rituximab and fludarabine combination therapy for chronic cold agglutinin disease [11th congress of the European Hematology Association, Amsterdam. Haematologica 2006; 91(Suppl 1):11 (Abstract 0027).
23. Treon SP, Hatjiharissi E, Leleu X, et al. Novel agents in the treatment of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2007; 7(suppl 5): S199-S206.
24. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-23.
25. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenstrom''s macroglobulinemia. Ann Oncol 2005; 16:132-8.